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Background	
Recent	evidence	has	highlighted	the	potential	role	of	complement	component	4	(C4)	in	the	
development	of	schizophrenia.	However,	it	remains	unclear	whether	C4	is	also	relevant	for	
clinical	outcome	and	if	it	could	be	considered	a	possible	therapeutic	target.		
Supporting	the	role	of	C4	in	psychosis,	Sekar	et	al	have	shown	that	the	association	of	
schizophrenia	with	variation	in	the	Major	Histocompatibility	Complex	locus	(Schizophrenia	
Working	Group	of	the	Psychiatric	Genomics	Consortium,	2014)	arises	in	substantial	part	
from	many	structurally	diverse	alleles	of	the	C4	gene	(Sekar	et	al.,	2016).	A	recent	study	also	
showed	that	schizophrenia	risk-associated	variants	in	the	C4	locus	are	associated	with	
increased	complement	neuronal	deposition	and	synapse	uptake	which	has	been	suggested	
as	possible	mechanism	mediating	the	development	of	psychotic	symptoms	(Sellgren	et	al.,	
2019).	We	have	previously	reported	alterations	in	the	complement	biomarkers	in	patients	
with	first	episode	psychosis	compared	with	healthy	controls	(Kopczynska	et	al.,	2019)	and	
another	recent	study	has	identified	elevated	levels	of	C4	in	patients	with	chronic	
schizophrenia	and	in	subjects	at	ultra-high	risk	of	developing	psychosis	(Laskaris	et	al.,	
2019).		
We	have	previously	shown	that	other	immune	biomarkers,	such	as	interleukin-6,	interferon-
γ	and	C	reactive	protein	predict	worse	clinical	outcome	at	3-months	or	1-year	follow-ups	in	
patients	with	first	episode	psychosis	(Mondelli	et	al.,	2015;	Nettis	et	al.,	2019),	but	no	study	
so	far	has	investigated	the	role	of	C4	in	clinical	outcome	in	psychosis.	The	aim	of	this	study	
was	to	investigate	whether	baseline	levels	of	C4	predict	worse	clinical	outcome	at	1-year	
follow-up	in	patients	with	first	episode	psychosis.	
	
Methods	
This	is	a	naturalistic	longitudinal	study	where	n=25	patients	with	first	episode	psychosis	
were	assessed	at	baseline	(i.e.	as	soon	as	possible	and	within	3	months	after	the	first	
contact	with	psychiatric	services)	and	then	followed-up	prospectively	for	their	clinical	
outcome	at	1	year	from	baseline	assessment.	Patients	were	recruited	as	part	of	the	Genetics	
and	Psychosis	(GAP)	study	and	we	refer	to	our	previous	publication	for	detailed	information	
about	recruitment	and	clinical	assessment	of	the	participants	(Mondelli	et	al.,	2015;	Nettis	
et	al.,	2019).	Severity	of	psychopathology	at	baseline	was	measured	using	the	Positive	and	
Negative	Syndrome	Scale	(PANSS).		
Information	about	clinical	outcome	at	1-year	was	obtained	using	the	WHO	Personal	and	
Psychiatric	History	Schedule	(PPHS)	(WHO,	1995).	Patients	were	defined	as	non-responders	
if	they	presented	at	1-year	follow-up	with	either	continuous	illness	or	with	one	or	more	
relapses	with	personality	change,	while	they	were	categorized	as	responders	if	they	either	
met	complete	recovery	or	no	relapses	with	residual	personality	changes	or	one	or	more	
relapses	with	no	marked	personality	change.	According	to	these	criteria	n=12	patients	were	
classified	as	non-responders	(mean±SEM	age:	33.2±3.7	years,	n=10	males)	and	n=13	as	
responders	(age:	27.5±	1.8	years,	n=9	males).		
Baseline	serum	samples	were	aliquoted	and	stored	at	-80°C	and	not	subjected	to	freeze-
thaw	until	analyses.	Concentrations	of	complement	component	4	(C4)	were	measured	using	
established	in-house	enzyme-linked	immunosorbent	assays	(ELISA).	Detailed	procedure	for	
analyses	of	C4	in	this	sample	has	been	previously	published	(Kopczynska	et	al.,	2019).	C-
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reactive	protein	(CRP)	was	measured	using	a	commercial	ELISA	(CRP	Duoset	DY1707;	R&D	
Systems,	Abingdon,	UK).		
Data	were	analysed	using	the	Statistical	Package	for	Social	Sciences	version	24.0	(SPSS	Inc.,	
USA).	ANCOVA	analyses	were	conducted	to	investigate	differences	in	baseline	C4	levels	
between	responders	and	non-responders	at	1-year	covarying	for	baseline	severity	of	
symptoms	(total	score	of	PANSS)	and	for	level	of	C	reactive	protein.	We	then	conducted	
Receiver	Operating	Characteristic	(ROC)	curve	analyses	to	test	the	ability	of	C4	levels	to	
correctly	identify	non-responders	from	responders.	
	
Results	
Non-responders	show	significantly	higher	baseline	C4	levels	compared	with	responders	
when	controlling	for	baseline	psychopathology	and	baseline	levels	of	C	reactive	protein	
(552.5±31.3	vs	437.6±25.5	mcg/ml;	p=0.008;	see	Figure	1).	When	investigating	the	ability	of	
C4	levels	to	distinguish	responders	from	non-responders,	we	found	that	the	area	under	the	
ROC	curve	was	0.795	and	the	threshold	point	for	C4	to	distinguish	between	responders	and	
non-responders	appear	to	be	around	490	mcg/ml	(see	Figure	2).	
	
Figure	1:	Box	plots	of	C4	levels	in	Responders	and	Non-Responders,	showing	the	distribution	
of	the	data	based	on	the	five	summary	numbers:	minimum	value,	first	quartile,	media,	third	
quartile,	and	maximum	value.		
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Figure	2:	The	ROC	curve	for	levels	of	C4	predicting	response	to	treatment	
 
	
Discussion	
Our	findings	show	baseline	C4	levels	predict	clinical	outcome	at	1-year	follow-up	in	patients	
with	first	episode	psychosis.	The	value	of	the	area	under	ROC	curve	suggests	baseline	C4	
levels	could	be	a	good	biomarker	to	distinguish	non-responders	from	responders.	
Interestingly	the	threshold	at	which	C4	appears	to	distinguish	responders	from	non-
responders	was	found	to	be	at	490	mcg/ml,	which	is	just	above	what	is	considered	to	be	
normal	range	in	clinical	test	(160-480	mcg/ml).	Our	findings	suggest	a	possible	a	relevant	
clinical	threshold	for	future	studies	testing	the	role	of	C4	in	clinical	outcome	in	psychosis.	
The	mechanisms	through	which	increased	C4	levels	could	contribute	to	worse	clinical	
outcome	may	involve	an	excessive	synaptic	pruning	induced	by	an	increased	C4	deposition	
at	synaptic.	Indeed,	Sellgren	et	al,	have	recently	shown	that	schizophrenia	risk-associated	
variants	within	the	human	complement	component	4	locus	are	associated	with	increased	
neuronal	complement	deposition	and	synapse	uptake	(Sellgren	et	al.,	2019).	Future	studies	
would	need	to	test	the	efficacy	of	possible	therapeutic	strategies	targeting	C4	or	synaptic	
pruning	as	main	hypothesised	mechanism	linking	excess	of	C4	to	worse	clinical	outcome.		
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